Cita APA (7th ed.)
Kumar, P., Johnson, M., Molina, J., Rizzardini, G., Cahn, P., Bickel, M., . . . Greaves, W. (Nov 2018). LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofy229.2176
Cita Chicago (17th ed.)
Kumar, Princy, et al. "LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial." Open Forum Infectious Diseases Nov 2018. https://doi.org/10.1093/ofid/ofy229.2176.
Cita MLA (9th ed.)
Kumar, Princy, et al. "LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial." Open Forum Infectious Diseases, Nov 2018, https://doi.org/10.1093/ofid/ofy229.2176.
Atenció: Aquestes cites poden no estar 100% correctes.